Expression and Prognostic Value of Matrix Metalloproteinase-7 in Colorectal Cancer

  • Yang, Bo (Department of Oncology, Wuhan General Hospital of Guangzhou Command PLA) ;
  • Su, Ke (Department of Pathology and Pathophysiology, Wuhan University) ;
  • Gao, Jianfei (Department of Oncology, Wuhan General Hospital of Guangzhou Command PLA) ;
  • Rao, Zhiguo (Department of Oncology, Wuhan General Hospital of Guangzhou Command PLA)
  • Published : 2012.03.31


The purpose of this study was to evaluate expression and prognostic value of matrix metalloproteinase-7 (MMP-7) in colorectal cancer (CRC) patients. CRC tissues and corresponding distal normal mucosa tissues of 118 CRC patients were assessed by immunohistochemistry. Correlations between MMP-7 expression, patients' clinic pathological features, and overall survival rate were analyzed. We found that positive expression of MMP-7 in CRC tissues was significantly higher than that in distal normal mucosa (61.0% vs. 39.8%, p =0.001). Poor histological differentiation, advanced clinical stage and lymph node metastasis were significantly correlated with MMP-7 expression in CRC. The overall survival rate was significantly higher in the MMP-7 negative group than the positive group (Log-rank test= 9.957, p= 0.002). MMP-7 appeared as a significant independent prognostic factor through multivariate survival analysis. Collectively, we found MMP-7 expression to be correlated with progression and metastasis of CRC and thus could be used as a predictive marker of prognosis in CRC patients.


  1. Brinckerhoff CE, Matrisian LM (2002). Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol, 3, 207-14.
  2. Crawford HC, Scoggins CR, Washington MK, et al (2002). Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest, 109, 1437-44.
  3. Davis NC, Evans EB, Cohen JR, et al (1984). Staging of colorectal cancer, the Australian clinico-pathological staging (ACPS) system compared with Dukes' system. Dis Colon Rectum, 27, 707-13.
  4. de Vicente JC, Lequerica-Fernández P, Santamaría J, et al (2007). Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med, 36, 415-24.
  5. Ii M, Yamamoto H, Adachi Y, et al (2006). Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med, 231, 20-7.
  6. Ito Y, Yoshida H, Kakudo K, et al (2006). Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma. Pathology, 38, 421-5.
  7. Knox JD, Boreham DR, Walker JA, et al (1996). Mapping of the metalloproteinase gene matrilysin (MMP7) to human chromosome 11q21-->q22. Cytogenet Cell Genet, 72, 179-82.
  8. Lafleur MA, Handsley MM, Edwards DR (2003). Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med, 5, 1-39.
  9. Liu D, Nakano J, Ishikawa S, et al (2007). Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer, 58, 384-91.
  10. Liu H, Zhang T, Li X, et al (2008). Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci, 99, 2185-92.
  11. Long N, Moore MA, Chen W, et al (2011). Cancer epidemiology and control in north-East Asia past, present and future. Asian Pac J Cancer Prev, 11, 107-48.
  12. Masaki T, Matsuoka H, Sugiyama M, et al (2001). Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer, 84, 1317-21.
  13. Matthew F Leeman, Stephanie Curran, Graeme I Murray (2003). New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol, 201, 528-34.
  14. Safranek J, Holubec L Jr, Topolcan O, et al (2007). Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer. Anticancer Res, 27, 2953-6.
  15. Sternlicht MD, Werb Z (2001). How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol, 17, 463-76.
  16. Wilson CL, Matrisian LM (1996). Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol, 28, 123-36.

Cited by

  1. Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer vol.29, pp.5, 2012,
  2. Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review) vol.1, pp.6, 2013,
  3. Preoperative Levels of Matrix Metalloproteinase-7 and -9 and Tissue Inhibitor of Matrix Metalloproteinase-1 Relation to Pathologic Parameters in Bladder Carcinoma Patients vol.14, pp.2, 2013,
  4. Overexpression of Reg4, alone or combined with MMP-7 overexpression, is predictive of poor prognosis in colorectal cancer vol.33, pp.1, 2014,
  5. Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients vol.35, pp.4, 2014,
  6. Prognostic value of matrix metalloproteinase-7 expression in patients with non-small cell lung cancer vol.35, pp.4, 2014,
  7. Matrix metalloproteinase-7 and matrix metalloproteinase-25 in oral tongue squamous cell carcinoma vol.36, pp.12, 2014,
  8. -D-glucoside on the Formation of Aberrant Crypt Foci in Azoxymethane-Induced Colorectal Cancer in Rats vol.2017, pp.2314-6141, 2017,
  9. Role of MMP-7 in the pathogenesis of systemic lupus erythematosus (SLE) vol.26, pp.9, 2017,